Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis
- 5 January 2018
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 103 (4) , e165-e168
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosisBlood, 2017
- Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid‐directed monoclonal antibodyAmerican Journal of Hematology, 2016
- Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosisLeukemia, 2016
- Guidelines on the management of AL amyloidosisBritish Journal of Haematology, 2014
- Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)Haematologica, 2014
- A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosisBlood, 2013
- Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosisLeukemia, 2012
- Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain MeasurementsJournal of Clinical Oncology, 2012
- Amyloidosis: Pathogenesis and New Therapeutic OptionsJournal of Clinical Oncology, 2011
- Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic AmyloidosisJournal of Clinical Oncology, 2004